Beyett, Tyler S. http://orcid.org/0000-0001-5509-7004
To, Ciric http://orcid.org/0000-0002-6333-3174
Heppner, David E. http://orcid.org/0000-0002-0722-5160
Rana, Jaimin K.
Schmoker, Anna M. http://orcid.org/0000-0003-2830-5650
Jang, Jaebong
De Clercq, Dries J. H.
Gomez, Gabriel
Scott, David A. http://orcid.org/0000-0003-3243-528X
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Jänne, Pasi A. http://orcid.org/0000-0002-7821-4928
Eck, Michael J. http://orcid.org/0000-0003-4247-9403
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (RO1CA201049, PO1CA154303, P30GM124165, P41GM103403, S10OD021527)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1F32CA247198-01)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
DOE | Advanced Research Projects Agency - Energy (DE-AC02-06CH11357)
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 23 February 2022
Accepted: 19 April 2022
First Online: 9 May 2022
Competing interests
: M.J.E. is a consultant to Novartis, and the Eck laboratory receives or has received research funding from Novartis, Takeda, Sanofi, and Arbella. P.A.J. has received consulting fees from AstraZeneca, Boehringer Ingelheim, Pfizer, Roche/Genentech, Takeda Oncology, ACEA Biosciences, Eli Lilly and Company, Araxes Pharma, Ignyta, Mirati Therapeutics, Novartis, LOXO Oncology, Daiichi Sankyo, Sanofi Oncology, Voronoi, SFJ Pharmaceuticals, Takeda Oncology, Transcenta, Silicon Therapeutics, Syndax, Nuvalent, Bayer, Esai, Biocartis, Allorion Therapeutics, Accutar Biotech and Abbvie; receives post-marketing royalties from DFCI owned intellectual property on EGFR mutations licensed to Lab Corp; has sponsored research agreements with AstraZeneca, Daichi-Sankyo, PUMA, Boehringer Ingelheim, Eli Lilly and Company, Revolution Medicines, and Astellas Pharmaceuticals; and has stock ownership in Gatekeeper Pharmaceuticals. N.S.G. is a founder, science advisory board member (SAB) and equity holder in Syros, C4, Allorion, Jengu, B2S, Inception, EoCys, Larkspur (board member) and Soltego (board member). The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield, and Sanofi. The remaining authors declare no competing interests.